abrdn Life Sciences InvestorsHQL
Market Cap: $425M
About: abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
24% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 25
4% more capital invested
Capital invested by funds: $122M [Q1] → $127M (+$4.44M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
1.56% less ownership
Funds ownership: 34.28% [Q1] → 32.72% (-1.56%) [Q2]
6% less funds holding
Funds holding: 77 [Q1] → 72 (-5) [Q2]
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Research analyst outlook
We haven’t received any recent analyst ratings for HQL.